NEW YORK VC BACKS AUSTRALIAN LONGEVITY STARTUP EVERLAB IN $15 MILLION DEAL

With fresh capital in hand and a bold vision for global expansion, Everlab is stepping onto the world stage at a time when the world is ready to listen. It’s not about adding years to your life—it’s about adding life to your years. And if Everlab gets it right, this may be one of the most transformative health stories of the decade.

It’s not every day that a Melbourne startup captures the attention—and the checkbook—of one of New York’s most ambitious venture capital firms. But that’s exactly what’s happened with Everlab, a preventive healthcare company that’s positioning itself as the future of longevity.

Imagine walking into a clinic, undergoing a full-body scan that takes under an hour, and walking out with insights that could potentially add decades to your life. No symptoms. No waiting for something to go wrong. Just early detection, advanced analytics, and a blueprint for lifelong health. That’s the Everlab promise, and it’s this vision that’s sparked the interest of Left Lane Capital, the transatlantic VC powerhouse known for backing bold, high-growth ventures.

In one of the largest seed funding rounds seen in Australia this year, Everlab has secured a $15 million capital injection. The move marks not just a milestone for the company but a turning point in the global healthcare narrative: a shift from reactive treatment to proactive, data-driven longevity.

Everlab burst onto the scene in early 2024 following a $3 million pre-Seed raise in December 2023, backed by a lineup of high-profile investors including Ten13, AfterWork, Flying Fox, and the founders of Go1, Aconex, and Temedica. The Melbourne-based startup, founded by Marc Hermann—who previously co-founded and sold the wellness brand Foodspring to Mars in 2019—aims to radically shift the healthcare paradigm from reactive treatment to proactive longevity. By blending advanced diagnostics, AI-driven automation, and clinical insights, Everlab delivers personalized health strategies designed to prevent chronic disease and extend lifespan. Its tiered subscription model taps into a growing audience of health-focused consumers, many inspired by the high-performance biohacking approach popularized by US tech figure Bryan Johnson and his “Project Blueprint.”

The demand has been striking: Everlab has tens of thousands of people on its waitlist and is on pace for 20x growth this year alone. Hermann describes the platform as a fusion of AI and top-tier clinical expertise, delivering smarter, earlier interventions that empower users long before symptoms appear.

Left Lane Capital’s Laura Sillman, one of the startup’s enthusiastic backers, notes that while preventive care has long been an aspiration in medicine, Everlab has found a way to make it commercially viable. “They’ve built a product and model that makes it scalable—combining clinical depth with software leverage and operational precision,” she said.

With this momentum, Everlab is positioning itself not just as a wellness brand, but as a category-defining force in the future of personalized, preventive healthcare.

A Bold Mission, Backed by Global Capital

Everlab isn’t your average health-tech startup. The company has crafted what it claims to be the most advanced longevity solution available today. At the heart of its service is a comprehensive full-body MRI scan that can screen for over 1,000 diseases—many of which often go undetected until it’s too late.

But Everlab’s value proposition goes far beyond diagnostics. It offers a continuous care model that includes personalized health optimization plans, biomarker tracking, and long-term coaching designed to help clients extend both lifespan and healthspan. The result? A healthcare experience that is more predictive than prescriptive, rooted in prevention rather than crisis.

And now, thanks to the backing of Left Lane Capital, this experience is about to go global.

The Road to $15 Million

Raising capital is never easy, even in a health-conscious post-pandemic world where longevity and wellness are buzzwords. For Everlab, however, the pitch was compelling: give people the tools to stay healthy before they ever get sick. This core philosophy resonated with Left Lane Capital, whose portfolio includes some of the world’s fastest-growing consumer and technology businesses.

The $15 million seed round closed in early 2025 and immediately became one of the largest early-stage investments in Australia for the year. It was also a rare show of confidence from an overseas investor in a local startup that had, until recently, operated solely within Australian borders.

With this new funding, Everlab plans to scale its operations rapidly across Europe, the United States, and the Asia-Pacific region in 2026. Its expansion is already in motion, with strategic partnerships being pursued in major urban centers where demand for preventive healthcare is skyrocketing.

Changing the Healthcare Narrative

To understand the significance of Everlab’s model, it helps to look at the current state of healthcare. Globally, most systems remain reactive. You feel unwell, you see a doctor, and only then does the investigation begin. For many chronic and fatal diseases—cancer, cardiovascular issues, neurological disorders—this approach comes too late.

Everlab turns that model on its head. Its clients are, by definition, asymptomatic. They’re not looking for treatment; they’re seeking insight. This paradigm shift has profound implications not only for individual health outcomes but for public health systems burdened by late-stage disease treatment and escalating costs.

Instead of waiting for illness, Everlab proposes anticipating it. Its platform combines full-body imaging, advanced AI diagnostics, and ongoing preventative strategies. The goal isn’t just to detect disease, but to optimize performance and promote long-term vitality.

It’s a vision that’s long been discussed in medical circles but has rarely been executed at scale. Everlab believes that’s about to change—and the $15 million funding round is just the beginning.

As the longevity revolution gathers pace, the question isn’t whether preventive care like Everlab’s will go mainstream—it’s how quickly. In a world increasingly focused on health, wellness, and optimization, the time for reactive medicine may finally be running out.

A Growing Global Movement

Everlab’s rise also aligns with a broader global movement toward longevity science. From Silicon Valley to Singapore, billionaires, biohackers, and scientists are pouring time and money into cracking the code of aging. Companies like Altos Labs, Calico, and Human Longevity Inc. have dominated headlines with moonshot projects aiming to slow or even reverse aging.

Everlab takes a more grounded, immediately actionable approach. Rather than searching for the mythical “cure” for aging, it’s focused on empowering individuals with data, diagnostics, and coaching they can use now. It’s less about immortality and more about maximizing the quality—and quantity—of years.

This distinction is important. While the longevity industry is often criticized for being elitist or speculative, Everlab is working to make preventive health accessible and practical for a wider audience. Its model is built not on hype, but on evidence-based interventions and medical expertise.

The Power of Prevention

The power of prevention in medicine is well-established but underutilized. Studies consistently show that early detection significantly improves outcomes for conditions like cancer and heart disease. The challenge has always been cost, access, and infrastructure.

With full-body MRI scans now becoming faster and more affordable, Everlab is seizing a window of opportunity. Its clinics are equipped with cutting-edge imaging technology and supported by a cloud-based analytics platform that provides rapid, comprehensive reports. The client journey doesn’t end with the scan. It continues with tailored health plans, regular check-ins, and ongoing support—effectively replacing fragmented care with a continuous health partnership.

The combination of convenience, technology, and coaching is what makes Everlab a standout. And it’s also what has investors excited about its future.

Looking Ahead: Risk, Reward, and Responsibility

Of course, with rapid growth comes responsibility. Scaling healthcare is notoriously complex. Regulatory hurdles, data privacy concerns, and regional medical standards vary widely across markets. There’s also the challenge of ensuring clinical integrity and quality of care at scale.

Everlab’s leadership team is well aware of these obstacles. According to insiders, much of the $15 million will be allocated toward building the infrastructure necessary to maintain medical excellence while expanding internationally. Hiring top-tier medical professionals, upgrading data security protocols, and aligning with international standards are all part of the roadmap.

There’s also the broader ethical question of who gets access to this kind of care. Will Everlab remain a service for the health-obsessed elite, or will its model eventually trickle down to become a staple of public health policy? That remains to be seen, but the company’s mission suggests inclusivity is a long-term goal.

A Smarter Way to Stay Well

In the end, Everlab represents more than just another startup with a fancy scan. It’s a symbol of what healthcare could look like in the 21st century—proactive, data-driven, deeply personalized, and globally connected. It offers a smarter way to stay well, empowering people to live longer, healthier lives by detecting problems before they ever become symptoms.

With fresh capital in hand and a bold vision for global expansion, Everlab is stepping onto the world stage at a time when the world is ready to listen. It’s not about adding years to your life—it’s about adding life to your years. And if Everlab gets it right, this may be one of the most transformative health stories of the decade.

As the longevity revolution gathers pace, the question isn’t whether preventive care like Everlab’s will go mainstream—it’s how quickly. In a world increasingly focused on health, wellness, and optimization, the time for reactive medicine may finally be running out.

---

Note: The information provided in this article is intended for informational purposes only and does not constitute medical advice. Always consult a healthcare provider before starting any new supplement or health regimen.

---